273
Views
3
CrossRef citations to date
0
Altmetric
Letters to the Editor

Analysis of serum lipids, cardiovascular risk, and indication for statin use during nilotinib and imatinib therapy in de novo CML patients – results from real-life prospective study

, , , , , , , , , , , & show all
Pages 494-496 | Received 09 May 2019, Accepted 19 Sep 2019, Published online: 03 Oct 2019
 

Disclosure statement

T.H. – no relevant conflict of interest; L.S. – no relevant conflict of interest; D.Z. serves as a consultant for Novartis, Bristol Myers Squibb, Angelini and Incyte; B.W. – no relevant conflict of interest; Z.S. – no relevant conflict of interest; J.P. declares no relevant conflict of interest; P.B. – no relevant conflict of interest; L.S. – no relevant conflict of interest, P.R. – serves/d as a consultant for Novartis; Z.R. received research funding from Novartis, Bristol Mayer Squibb and serves on a speakers bureau for Novartis and Bristol Myers Squibb; J.M. received research funding from Novartis, Angelini, Bristol Mayer Squibb and serves on a speakers bureau for Novartis and Bristol Myers Squibb.

Additional information

Funding

The study was performed on behalf of the CELL – the CzEch Leukemia Study Group – for Life and supported by the Ministry of Health of the Czech Republic, grant No. [17-30397A] (all rights reserved).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.